Caris Life Sciences (CAI) EBT Margin (2024 - 2026)

Caris Life Sciences' EBT Margin history runs 3 years deep, the most recent figure standing at 0.3% for Q1 2026.

• On a quarterly basis, EBT Margin rose 8454.0% year-over-year to 0.3% in Q1 2026; TTM through Mar 2026 was 3.73%, a 6416.0% increase from a year earlier, with the FY2025 full-year figure at 8.38%, up 5999.0% from the prior year.
• EBT Margin declined to 0.3% in Q1 2026 per CAI's latest filing, from 27.98% in the prior quarter.
• Across five years, EBT Margin topped out at 27.98% in Q4 2025 and bottomed at 84.84% in Q1 2025.
• The 3-year median for EBT Margin is 34.01% (2024), against an average of 30.84%.
• Across the five-year window, EBT Margin soared 2658 bps in 2025 and surged 8454 bps in 2026, its largest moves.
• Year by year, EBT Margin stood at 28.44% in 2024, then soared by 198 bps to 27.98% in 2025, then slumped by 101 bps to 0.3% in 2026.
• Per Business Quant, the three latest CAI EBT Margin figures stand at 0.3% (Q1 2026), 27.98% (Q4 2025), and 11.22% (Q3 2025).